At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)
In Brief
A Phase 2 clinical trial evaluating enzalutamide, mifepristone, and 2 other interventions for Hormone-resistant Prostate Cancer and 2 related conditions. Completed, enrolled 88 participants across 4 sites.
Detailed Summary
This partially randomized phase I/II trial studies the side effects and best dose of enzalutamide and mifepristone when given together and to see how well they work in treating patients with metastatic hormone resistant prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as enzalutamide and mifepristone, may lessen the amount of androgens made by the body. It is not yet known whether enzalutamide is more effective with or without mifepristone in treating patients with prostate cancer.
Study Details
Timeline
Interventions
Given PO
Given PO
Correlative studies
Correlative studies